Trial Profile
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 14 Apr 2024 Planned End Date changed from 1 Jun 2022 to 1 Jun 2025.
- 14 Apr 2024 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2024.
- 01 Apr 2022 Results published in the Leukemia